𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Influence of human interferon-α therapy on cytotoxic functions of blood lymphocytes

✍ Scribed by Stefan Einhorn; Henric Blomgren; Hans Strander; Jerzy Wasserman

Publisher
Springer-Verlag
Year
1983
Tongue
English
Weight
404 KB
Volume
16
Category
Article
ISSN
0340-7004

No coin nor oath required. For personal study only.

✦ Synopsis

Various cytotoxic functions of blood lymphocytes were studied in 101 patients undergoing daily treatment with human interferon-a (IFN). Antibody-dependent cellular cytotoxicity and lectin-dependent cellular cytotoxicity were not altered to any major extent after 1 day or 1 week of lFN therapy. After 3 and 6 months of treatment a decrease in these functions was observed in most patients. Natural killer cell activity increased following the first injection of IFN and remained elevated during 1 year of IFN therapy.

📜 SIMILAR VOLUMES

Cytotoxicity of human rosette-forming bl
Cytotoxicity of human rosette-forming blood lymphocytes on cultivated human tumor cells
✍ Joseph Wybran; Ingegerd Hellström; Karl Erik Hellström; H. Hugh Fudenberg 📂 Article 📅 1974 🏛 John Wiley and Sons 🌐 French ⚖ 481 KB

## Abstract Human peripheral blood lymphocytes from seven cancer patients were separated into two fractions, one rich in lymphocytes which could spontaneously form rosettes with sheep erythrocytes (T‐cells) and another poor in rosette‐forming cells. These two fractions were then tested for cytotoxi

Down-regulation of peripheral blood cell
Down-regulation of peripheral blood cell interferon receptors in chronic myelogenous leukemia patients undergoing human interferon (HuIFNα) therapy
✍ Beth Lynn Maxwell; Moshe Talpaz; Jordan U. Gutterman 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 French ⚖ 608 KB

## Abstract Our interest in studying interferon (IFN) receptor activity in peripheral blood cells (PBCs) from patients with chronic myelogenous leukemia (CML) receiving therapeutic doses of partially purified leukocyte IFN (IFNα) stems from a need for more adequate monitoring of IFN therapy. The bi